Theriva Biologics, Inc.
TOVX
$0.25
$0.014.52%
AMEX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 43.00% | 13.06% | -26.76% | 541.73% | -16.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -45.05% | -35.43% | -14.43% | 179.70% | -14.89% |
| Operating Income | 51.85% | 35.43% | 14.43% | -179.70% | 14.89% |
| Income Before Tax | 52.73% | 55.12% | 43.55% | -57.02% | 16.28% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 52.73% | 55.12% | 43.55% | -57.02% | 16.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 52.73% | 55.12% | 43.55% | -57.02% | 16.28% |
| EBIT | 51.85% | 35.43% | 14.43% | -179.70% | 14.89% |
| EBITDA | 52.11% | 35.65% | 14.42% | -181.40% | 14.75% |
| EPS Basic | 96.80% | 92.48% | 93.38% | 81.96% | 79.36% |
| Normalized Basic EPS | 96.80% | 93.79% | 89.81% | 66.84% | 78.52% |
| EPS Diluted | 96.80% | 92.48% | 93.38% | 81.96% | 79.36% |
| Normalized Diluted EPS | 96.80% | 93.79% | 89.81% | 66.84% | 78.52% |
| Average Basic Shares Outstanding | 1,376.16% | 948.20% | 753.01% | 770.57% | 305.66% |
| Average Diluted Shares Outstanding | 1,376.16% | 948.20% | 753.01% | 770.57% | 305.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |